PPD strings together a site network for pediatric trials

PPD, angling to stand out among CROs running pediatric trials, has cemented a network of 8 global sites to accelerate the process of starting studies on kids.

The idea, according to PPD, is to offer sponsors a predictable, scalable model for pediatric trials of all sizes, smoothing out the thorny early stages of planning a study. Having a go-to network of trusted sites allows for quick preparations, easier enrollment and, ultimately, higher-quality data, according to the company.

The 8-center network includes Columbia University, Seattle Children's Research Institute, Schneider Children's Medical Center of Israel and a pair of National Health Service centers in the U.K.

Drug developers and global regulators are increasingly recognizing the importance of running pediatric trials on in-development products, especially in rare diseases, and PPD believes its efforts make it a leader among CROs in the field.

"Our network already has been working effectively with our clients to provide state-of-the-art clinical trial delivery across the globe," Dr. Mark Sorrentino, PPD executive medical director, said in a statement. "Building formal relationships with strategically important centers that have significant pediatric clinical trial expertise, a proven track record of superior quality and the ability to recruit pediatric patients demonstrates our commitment to partnering with our clients to bring life-changing medications to market faster and at less cost."

PPD is plotting to expand its network over the coming years, working to recruit new centers of excellence.

- read the statement

Suggested Articles

WuXi AppTec has cut the ribbon on its expanded Laboratory Testing Division in New Jersey as it looks to boost its integrated testing service portfolio.

St. Jude, Microsoft and DNAnexus have created a data-sharing and analysis platform to help accelerate pediatric cancer research.

The money will be used to expand its footprint in both China and the U.S., including a new R&D operation in Boston.